Total Funding
41
32
Total FundingSeries B raised
Growth Score
-14 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
36509
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
- Past Role: Sangamo Therapeutics, EVP Corporate Strategy
Mehdi Gasmi: COOPast Role: Genethon, VP Product Development & Manufacturing
About the Company
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all
genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
